Most Effective UC Medication for Clinical Remission

Evidence Hierarchy and Treatment Selection

The American Gastroenterological Association recommends upadacitinib as the single most effective medication for inducing clinical remission in biologic-naïve patients with moderate-to-severe ulcerative colitis, achieving remission in approximately 49% of patients, with moderate-to-high certainty evidence showing clinically important benefit over other advanced therapies 1, 2
Upadacitinib demonstrates superior efficacy with moderate-to-high certainty evidence, showing a clinically important benefit over infliximab, adalimumab, vedolizumab, etrasimod, ustekinumab, mirikizumab, tofacitinib, and filgotinib for inducing clinical remission, with an absolute remission rate of 49% 1, 2
The European Society of Gastrointestinal Endoscopy notes that the magnitude of benefit of upadacitinib meets the pre-specified minimal clinically important difference of 5% absolute risk difference compared to other active treatments, with moderate certainty evidence 1
The American College of Gastroenterology states that risankizumab and ozanimod are the most effective first-line options in the United States, where FDA restricts JAK inhibitors to second-line use, achieving approximately 35% clinical remission rates, with moderate certainty evidence 3

The American Gastroenterological Association recommends upadacitinib as the most effective agent for patients with prior biologic exposure, with moderate certainty evidence showing clinically important benefit over adalimumab, vedolizumab, ozanimod, etrasimod, mirikizumab, risankizumab, guselkumab, and filgotinib 1, 2
Tofacitinib demonstrates moderate certainty evidence of clinically important benefit in biologic-exposed patients, though with lower absolute efficacy than upadacitinib, according to the European Society of Gastrointestinal Endoscopy 1
IL-23 antagonists (risankizumab, mirikizumab, guselkumab) show moderate certainty evidence of benefit over placebo in biologic-exposed populations, as noted by the American College of Gastroenterology 2

Infliximab shows possibly important benefit over adalimumab, mirikizumab, tofacitinib, and filgotinib with low certainty evidence, according to the American Gastroenterological Association 4

The American Gastroenterological Association notes that upadacitinib demonstrates superior mucosal healing rates compared to all other advanced therapies in biologic-naïve patients, with moderate certainty evidence 1, 3

The American Gastroenterological Association recommends risankizumab as a first-line option, with an absolute risk difference of 182 per 1000 patients (95% CI: 3 to 544) vs placebo 5
Ozanimod has a clinical remission rate of ~35% with moderate certainty evidence, and its oral administration provides a convenience advantage 5
Vedolizumab demonstrates a clinical remission rate of 31.3% at 52 weeks, vs 22.5% for adalimumab (p=0.006) in the head-to-head VARSITY trial 6
Tofacitinib shows a clinical remission rate of 18.5% (OCTAVE-1) and 16.6% (OCTAVE-2) vs 8.2% and 3.6% placebo, respectively 6

Upadacitinib has a clinical remission rate with an absolute risk difference of 653 per 1000 (95% CI: 197 to 1000) vs placebo, and a relative risk of 14.05 (95% CI: 4.94-43.94) with moderate certainty evidence 5
Tofacitinib demonstrates a clinical remission rate with an absolute risk difference of 473 per 1000 (95% CI: 55 to 1000) vs placebo, and a relative risk of 10.45 (95% CI: 2.09-52.22) with moderate certainty evidence 5
Guselkumab has a clinical remission rate with an absolute risk difference of 93 per 1000 (95% CI: 20 to 244) vs placebo, and a relative risk of 2.86 (95% CI: 1.39-5.88) with moderate certainty evidence 5

The American Gastroenterological Association suggests combining TNF antagonists with thiopurines or methotrexate, rather than using TNF monotherapy, as combination therapy demonstrates superior remission rates 7
Prior anti-TNF exposure significantly reduces the efficacy of subsequent vedolizumab, with a hazard ratio of 0.53 for clinical remission and 0.51 for endoscopic remission 6
IL-23 antagonists and JAK inhibitors maintain superior efficacy even in biologic-exposed populations 5